Last reviewed · How we verify
GNR-060
GNR-060 is a small molecule drug that targets the SGLT2 receptor.
GNR-060 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | GNR-060 |
|---|---|
| Also known as | Tenecteplase |
| Sponsor | AO GENERIUM |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
GNR-060 works by inhibiting the SGLT2 receptor, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine and decreased glucose levels in the blood. As a result, GNR-060 is used to treat type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
- Genital infections
- Increased risk of amputations
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |